NCT06840119

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: Immunocore Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.

Conditions

• Cancer
• HLA-A*02:01-positive

Interventions

Type	Name	Description
DRUG	IMC-R117C	IV infusion
DRUG	Chemotherapy drug	IV infusion
DRUG	Chemotherapy drug	oral
DRUG	Kinase inhibitor	oral
DRUG	Antiangiogenic Agent	IV infusion
DRUG	Monoclonal antibody	IV infusion

Timeline

• Start date: 2024-01-10
• Primary completion: 2026-11-30
• Completion: 2027-11-30
• First posted: 2025-02-21
• Last updated: 2026-01-28

Locations

13 sites across 6 countries: Australia, Belgium, Germany, Italy, Netherlands, Spain